# A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis

> **NCT07321093** · PHASE3 · RECRUITING · sponsor: **Biocad** · enrollment: 292 (estimated)

## Conditions studied

- Relapsing-remitting Multiple Sclerosis (RRMS)

## Interventions

- **BIOLOGICAL:** BCD-281
- **BIOLOGICAL:** Ocrelizumab

## Key facts

- **NCT ID:** NCT07321093
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-01
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 292 (ESTIMATED)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07321093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07321093, "A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07321093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*